BridgeBio Pharma (BridgeBio Pharma) Change In Inventory

: $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

BridgeBio Pharma's change in inventory for the quarter that ended in Dec. 2023 was $0.00 Mil. It means BridgeBio Pharma's inventory stayed the same from Sep. 2023 to Dec. 2023 .

BridgeBio Pharma's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means BridgeBio Pharma's inventory stayed the same from Dec. 2022 to Dec. 2023 .

BridgeBio Pharma's Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. BridgeBio Pharma's Days Inventory for the quarter that ended in Dec. 2023 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BridgeBio Pharma's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.

BridgeBio Pharma Change In Inventory Historical Data

The historical data trend for BridgeBio Pharma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

BridgeBio Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory																-	-	-	-	-

BridgeBio Pharma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

BridgeBio Pharma (NAS:BBIO) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BridgeBio Pharma's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0.598	*	365 / 4
	=	0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

BridgeBio Pharma's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0.598	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BridgeBio Pharma's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	1.745
	=	0.00

BridgeBio Pharma Change In Inventory Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma (BridgeBio Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (NAS:BBIO) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

2CL:Germany

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

Executives

Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Frank Mccormick	officer: Chairman of Oncology	C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001
Randal W Scott	director	171 MAIN STREET #225, LOS ALTOS CA 94022
Neil Kumar	director, officer: See Remarks	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Brian C Stephenson	officer: See Remarks	3160 PORTER DR, STE 250, PALO ALTO CA 94304
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Douglas A. Dachille	director	175 WATER STREET, NEW YORK NY 10038
Andrew Lo	director	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Ronald J Daniels	director	C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901
Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
James C Momtazee	director	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Andrea Ellis	director	C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
Richard H Scheller	director, officer: See Remarks	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990